Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRX-NGT011
- Development stage
- Preclinical
- Lead developer
- Novorex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NRX-NGT011 is a small molecule drug candidate under development by Novorex for the treatment of undisclosed autoimmune diseases. The drug is currently in the hit discovery phase of development.
Beyond the preview
Go deeper on NRX-NGT011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRX-NGT011.